Candel Therapeutics Says FDA Granted Orphan Drug Designation To Oncolytic Viral Immunotherapy CAN-3110 For Treatment Of Recurrent High-Grade Glioma
Portfolio Pulse from Benzinga Newsdesk
Candel Therapeutics announced that the FDA has granted Orphan Drug Designation to its oncolytic viral immunotherapy, CAN-3110, for the treatment of recurrent high-grade glioma.

May 30, 2024 | 12:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Candel Therapeutics' CAN-3110 has been granted Orphan Drug Designation by the FDA for the treatment of recurrent high-grade glioma. This designation can provide benefits such as market exclusivity, tax credits, and assistance in clinical trial design.
The FDA's Orphan Drug Designation is a significant milestone for Candel Therapeutics as it can lead to market exclusivity, tax credits, and other benefits. This is likely to positively impact the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100